Subtype
Extrapulmonary Neuroendocrine Carcinoma
CI-CAN-00002658Explore in graph →
104 active trials6 approved drugs22 evidence items
- NCIt
- C191977
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002658Explore in graph →
Clinical trials
315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (50)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02409849 | Octreotide LAR as Maintenance Treatment for Patients With NEC | unknown | Phase 2 | 92 | Peking UniversityOTHER | 1 | Apr 7, 2015 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT00134043 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer |
| completed |
| Phase 2 |
| 19 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 11, 2014 |
| clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00004922 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00079131 | Oblimersen in Treating Patients With Merkel Cell Carcinoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | withdrawn | Phase 2 | 0 | Eanm Research LtdNETWORK | 1 | May 17, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00068783 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT01739634 | The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | unknown | Phase 1 / Phase 2 | 10 | Salient Pharmaceuticals IncorporatedINDUSTRY | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00003549 | S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer | completed | Phase 2 | 80 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 8, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 7, 2015source: clinicaltrials